Industry Roundup: FTC, FDA Enforcement, Mannatech CEO, Quell Distribution
This article was originally published in The Tan Sheet
Executive Summary
FTC commissioner questions enforcement; Mannatech adds CEO to Bala’s title; Quell wearable pain relief heads for stores; ED drug in ‘Herb Viagra’; and more news in brief.
You may also be interested in...
OTC Device Claims Regulation: FTC Targets Quell On Pain Relief, FDA Warns Zona Plus On BP
An FTC member doubts NeuroMetrix crossed all FDA regulatory lines in advertising for Quell wearable pain relief technology that attorneys alleged. FDA warning letter says Zona Health executives said they “would ‘remain in all regulatory guidelines’" when the agency in 2018 explained claims violations.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.